MSProDiscuss™ is a useful tool to aid discussion of multiple sclerosis disease progression: Results from a large, real-world qualitative survey

Tjalf Ziemssen[1], Gavin Giovannoni[2], Enrique Alvarez[3], Virender Bhan[4], Carrie Hersh[5], Olaf Hoffmann[6], Celia Oreja-Guevara[7], Rene R. Robles-Cedeño[8], Maria Trojano[9], Patrick Vermersch[10], Pamela Dobay[11], Mudeer Khwaja[12], Bianca Stadler[12], Thomas Hach[12], Daniela Piani-Meier[12], Jason Burton[13]

Poster Session: P0885

[1]Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany; [2]Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; [3]University of Colorado School of Medicine, Aurora, CO, United States of America; [4]University of British Columbia, Vancouver, BC, Canada; [5]Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States of America; [6]Alexianer St. Josef Potsdam GmbH, Potsdam, Germany; [7]Multiple Sclerosis Center at the University Hospital San Carlos, Madrid, Spain; [8]Neuroimmunology and Multiple Sclerosis Unit, Girona, Spain; [9]University of Bari, Bari, Italy, [10]Univ. Lille, Inserm U1172, CHU Lille, FHU Imminent, Lille, France; [11]Real World Evidence Solutions, IQVIA Technology and Services, Basel, Switzerland, [12]Novartis Pharma AG, Basel, Switzerland; [13]Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience Research Institute, The University of Western Australia, Perth, Australia

Poster Presentation at the 8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020, September 11-13

Scan to download copy of this presentation

Copyright © 2020 Novartis Pharma AG. All rights reserved

Disclosures

Tjalf Ziemssen has received compensation for consulting from Biogen, Bayer, Celgene, Novartis, Roche, Sanofi, and Teva and for research from Bayer, BAT, Biogen, Novartis, Teva, and Sanofi. GG has received compensation for consulting from AbbVie, Actelion, Atara Bio, Biogen, Celgene, Sanofi-Genzyme, Genentech, GlaxoSmithKline, Merck-Serono, Novartis, Roche and Teva, and for research from Biogen, Roche, Merck, Merck-Serono, Novartis, Sanofi-Genzyme and Takeda. He has received personal compensation from Elsevier for serving as an editor on MSARD.

Gavin Giovannoni is a steering committee member on the daclizumab trials for AbbVie, the BG12 and daclizumab trials for Biogen, the fingolimod and siponimod trials for Novartis, the laquinimod trials for Teva and the ocrelizumab trials for Roche. He has also received consultancy fees for advisory board meetings for oral cladribine trials for Merck KGaA and Sanofi-Genzyme, and in relation to DSMB activities for Synthon BV, as well as honoraria for speaking at the Physicians' summit and several medical education meetings. He is also the Co-Chief Editor of Multiple Sclerosis and Related Disorders (Elsevier).

Enrique Alvarez has received compensation for consulting from Actelion, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, Teva, and TG Therapeutics and for research from Biogen, Genentech, Novartis, and Rocky Mountain MS Center.

Virender Bhan has received compensation for consulting from Novartis.

Carrie Hersh has received compensation for consulting and research from Novartis, Biogen and Genentech and for consulting from EMD Serono and consulting and speaker bureau from Genzyme.

Olaf Hoffmann has received compensation for consulting from Biogen, Roche, Merck, Novartis, Sanofi, and Celgene, for non-CME activities from Alexion, Novartis, Roche and Sanofi and for research from Novartis, Sanofi and Biogen and travel support from Celgene.

Celia Oreja-Guevara has received compensation for speaking and/or consultancy from Biogen, Sanofi-Genzyme, Merck, Roche, Teva, and Novartis.

Rene R. Robles-Cedeño has received compensation for consulting from Biogen, Roche, Novartis, Merck, Sanofi, Genzyme and Teva.

Maria Trojano has received compensation for consulting and speaker bureau from Biogen, Merck. Roche and Novartis.

Patrick Vermersch has received honoraria and consulting fees from Biogen, Sanofi, Teva, Novartis, Merck, Celgene and Roche, and research support from Biogen, Sanofi, Roche and Merck. **Pamela Dobay** is an employee of IQVIA Technology and Services AG, Basel, Switzerland, which conducted this survey.

Jason Burton has received compensation for consulting and speaker bureau from Novartis.

Mudeer Khwaja, Bianca Stadler, Thomas Hach, and Daniela Piani-Meier are employees of Novartis.

The study was funded by Novartis Pharma AG, Basel, Switzerland..

Medical writing support was provided by **Gillipsie Minhas** and **Uma Kundu** (employees of Novartis Healthcare Pvt. Ltd., Hyderabad, India). The final responsibility for the content lies the authors.

Background and objective

- Multiple Sclerosis Progression Discussion (**MSProDiscuss™**) tool intended to facilitate physician-patient discussion on MS disease progression and to sensitize about the risk of transitioning from RRMS to SPMS[1-3]
- The tool is freely available online at www.msprodiscuss.com and on neurocompass educational portal

Objective

To evaluate the usability and usefulness of MSProDiscuss tool in discussing disease progression in daily clinical practice



MS, multiple sclerosis; RRMS, relapsing-remitting MS; SPMS, secondary progressive MS

1. Tolley C, et al. *JMIR Med Inform.* 2020;8(4):e17592. 2. Ziemssen T, et al. *J Med Internet Res*. 2020;22(2):e16932. 3. Ziemssen T, et al. *Mult Scler Relat Disord*. 2020;38:101861.

Methodology



Step 1
HCPs consented for participation in an online survey-based feedback on usability and usefulness of MSProDiscuss tool

Step 2
Initial questionnaire
HCPs completed individual questionnaire after each patient Consultation

Step 3
Final questionnaire
HCPs completed final questionnaire to capture overall experience, feedback and recommendations

Step 4
Data analysis
Feedback after completing the initial and final questionnaire were compiled separately and resented descriptively[1]

Target patient population

HCPs used MSProDiscuss on a broad range of MS patients excluding patients with CIS and PPMS

Test parameters

Understanding, usefulness, usability, and integration/ adoption of the MSProDiscuss tool into daily clinical practice

Evaluation parameters

Time needed for completion, comprehensibility of the questions included, usability and usefulness (**initial questionnaire**); additionally, integration into clinical practice (**final questionnaire**)[2]

[1]Both weighted and unweighted percentages were calculated. [2]Feedback was provided on a 5-point Likert scale
CIS, clinically isolated syndrome; HCP, healthcare practitioner; MS, multiple sclerosis; PPMS, primary progressive MS

Results

Survey Participants

Global survey: HCPs came from 34 countries

HCPs from North America, Europe, Asia, South America, Africa, and Australia participated in the usability and usefulness testing

There were 301 HCPs who participated in the survey

246 MS specialist neurologists

25 General neurologists

23 MS Nurses

6 Neurology nurse practitioners / physicians assistants

1 Other specialization

Tool was tested on a large number of patients

>6974 MS patients
77% RRMS

- HCPs participated in the online survey to provide their feedback between July and December 2019
- A total of 301 HCPs provided feedback on at least one questionnaire
- The HCPs also provided general feedback and recommendations for further improvement of the tool

HCP, healthcare practitioner; MS, multiple sclerosis; RRMS, relapsing-remitting MS

Majority of HCPs agreed or strongly agreed that MSProDiscuss is beneficial in their practice

- In over **97%** of the instances, HCPs indicated that the time taken to complete the tool was considered satisfactory **(1–4 minutes)**
- In **94%** of cases, HCPs felt that the patients understood the questions well
- **91%** were willing to use the tool again in the same patient
- The tool was found useful in discussing disease progression in general, MS symptoms and its impact on daily activities in **88%** of cases and cognitive function in **79%**

Feedback from initial questionnaire[a]



Results as of 31 Dec 2019. [a]Percentages are based on unweighted results; weighted results were similar
HCP, healthcare practitioner; MS, multiple sclerosis

Majority of HCPs think that it is feasible to integrate MSProDiscuss in their daily clinical practice



- **Overall feedback was similar to and consistent with the findings from the individual questionnaires**
- **9 out of 10 HCPs would recommend MSProDiscuss to a colleague and willing to integrate MSProDiscuss into their clinical practice**

Results as of 31 Dec 2019. [a]Percentages are based on unweighted results; weighted results were similar
HCP, healthcare practitioner; MS, multiple sclerosis

Recommendations on possible improvements



Recommendations for expanding MSProDiscuss, including additional variables that can be included
Add time of disease progression or duration of disease
Expand cognitive function and fatigue evaluation
Add adherence to treatment
Add more details on impact of disease on daily activities, e.g., relationships, social, work, sexuality, emotional state, etc.
Include / interface with cognitive assessment scales

HCPs described MSProDiscuss as a "good," "helpful," and "easy to use" tool in clinical practice

Several of the recommendations for improvement have already been implemented

[a]The items in grey boxes indicate actions already implemented in the updated version of the MSProDiscuss. A patient-completed "YourMS" questionnaire has been developed
HCP, healthcare practitioner; MS, multiple sclerosis

Feedback and improvements already implemented

Include longitudinal follow-up

Integration of MSProDiscuss in electronic-health record systems are ongoing, which will not only facilitate the tool's use, but also allow easier longitudinal follow-up and better visualization of results

Improve user interface

The user interface has been enhanced for easier navigation, and have eliminated any unnecessary interactions for a streamlined, less time-consuming experience

Improve tool sensitivity

The sensitivity of the tool was further improved for patients with lower EDSS scores and with confounding symptoms like fatigue

Provide self-administered version for patients



A patient version of the tool has been created (available at www.yourms.com) which can be pre-filled by the patient, potentially with help from the caregiver. YourMS covers all MS symptoms, and ensures that the patient comes to the consultation prepared

EDSS, Expanded Disability Status Scale; HCPs, healthcare practitioner

Conclusions

- MSProDiscuss is a usable and useful tool to facilitate physician-patient discussion on disease progression in daily clinical practice by capturing structured disease history
- The findings from this real-world study suggest that:
  - MSProDiscuss is **easy to use** (time taken to complete within routine consultation ranged from 1-4 mins)
  - Questions included in MSProDiscuss are **easy to comprehend by patients**, and are similar to what an HCP would normally ask in a consultation
  - MSProDiscuss is **easy to integrate into clinical practice**

Thank you

HCP, healthcare practitioner